Why Wall Street Is Betting Big on Weight-Loss Drugs in 2026

New York, Sunday, 21 June 2026.
GLP-1 drugs are reshaping markets—Nasdaq surged 2% in June as investors flock to biotech stocks. Novo Nordisk and Eli Lilly valuations soar, but smaller firms are now attracting venture capital. The shift reveals a rare bright spot in a high-rate economy: health tech as a defensive, high-growth play.